Sumitomo Pharma Co.,Ltd. [4506.T]
TOKYO, Apr 08 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) announced its intention to issue new shares through public offering and sell existing shares to raise funds for its strategic initiatives outlined in the “Boost 2028” plan.
The company aims to secure capital for accelerating the development and commercialization of key oncology and neuroscience products, enhancing research infrastructure, and strengthening its financial foundation. The total amount of capital increase will exceed the evaluation equity value of hybrid bonds issued in September 2020, leading to their early redemption. The issuance will also reduce the voting rights ratio held by parent company Sumitomo Chemical but maintain Sumitomo Pharma's status as a consolidated subsidiary. Additionally, the company plans to refinance debt without Sumitomo Chemical’s guarantee post-issuance.
In recent years, Sumitomo Pharma faced significant losses and stringent operational challenges, which led to restructuring efforts including personnel cuts and portfolio realignment. Despite these difficulties, the firm achieved profitability in fiscal 2024 and secured stable finances through refinancing existing debts. The new funding will support ongoing clinical trials for two cancer drugs, enhance partnerships with joint ventures such as RACTHERA and S-RACMO, and bolster production capabilities and IT investments. Sumitomo Pharma emphasizes sustainable dividend policies tied to performance improvements while maintaining robust investment in future growth opportunities.
The company’s approach underscores a commitment to balancing shareholder returns with long-term strategic objectives.
🔴 Confidence: Review recommended AI-translated content.